Search the webpage

Created by Simon Kaja on   July 11, 2018   in category: Scientific publications

Trabodenoson, an alpha1 adrenergic agonist, shows preclinical efficacy in a preclinical model for dry eye syndrome, according to a study co-authored by Experimentica Ltd.

According to the results of a study published in the June 2018 issue of Investigative Ophthalmology and Vision Research, trabodenoson eye drops reduced attenuated hallmark signs of dry-eye disease pathology, including corneal surface inflammation, lacrimal gland infiltration by immune cells and loss of mucin-producing goblet cells in the conjunctiva.

The study, conducted in collaboration with Inotek Pharmaceuticals Corp., K&P Scientific LLC and Loyola University Chicago, compared the preclinical efficacy with a marketed formulation of ophthalmic cyclosporine emulsion and concluded that trabodenoson showed similar or better preclinical efficacy, supporting the development of A1R-targeting pharmaceuticals for DED.

Experimentica Ltd. is a global contract research organization specialized in ocular models. Headquartered in Kuopio, Finland, Experimentica Ltd. focuses on Advancing Ophthalmic Drug DiscoveryTM by offering an industry-leading portfolio for ophthalmic drug development.

Contact for media enquiries: 

Dr. Simon Kaja
Chief Scientific Officer
Experimentica Ltd.
Phone: +1 (844) 393-49393
Email: kaja@experimentica.com

LATEST NEWS

New Board of Directors announced

News
Experimentica Ltd., a global contract research organization that specializes in preclinical models for ophthalmic diseases, is pleased to announce its ... Read More

New insights to the supporting mechanism of fluid management in the neural retina

News
Angiopoietin-4 was identified as the first growth factor having a venous-specific function in the mouse retina, according to a publication ... Read More

Experimentica Ltd. opens a new R&D site in Lithuania

News
The investment totaling €1.6 million was supported, in part, by a competitive award “Smart FDI” (project no. 01.2.1-LVPA-T-848-01-005) under the ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!